The dispute revolves around the CFTC's new policy that allows these specialized futures contracts, often called "perps," to trade on regulated U.S. exchanges. While CME Group challenged the approval in court, the CFTC is now attempting to cast doubt on the merits of the suit by highlighting the lack of proven harm to the exchange.
